Bacillus Coagulans
Identifiers
Hazards
Where is bacillus coagulans used, and what role does it play in each application?
Bacillus coagulans is used as a probiotic in food, beverage, pharmaceutical, and cosmetic applications. In food and pharmaceuticals, it is claimed to support digestive health, alleviate lactose intolerance, promote protein digestion, reduce blood glucose and uric acid, and address functional gastrointestinal disorders. In cosmetics, it appears in face washes and moisturizers under probiotic branding, suggesting a role in skin microbiome support. Patent filings also describe its use in anti-aging and intestinal flora regulation products, including pet food. Its role is consistently that of a live probiotic agent, often formulated as spores or in freeze-dried powders.
Which product or formulation problem does bacillus coagulans address?
Bacillus coagulans addresses formulation challenges related to probiotic stability and delivery. Patent evidence describes microencapsulation with inulin and xanthan gum, and freeze-drying with protectants like skim milk powder, fructooligosaccharides, and monosodium glutamate to maintain viability. It also solves product formulation problems by enabling combination with prebiotics and other probiotic strains in health supplement compositions. In consumer products, it is positioned to address skin microbiome concerns in rinse-off and leave-on formats. The spore-forming nature of the organism is a key advantage for shelf-stable formulations.
What supports the main commercial or clinical uses of bacillus coagulans?
The main uses are supported by strain-specific patent claims. Documented applications include alleviating lactose intolerance and promoting protein digestion (strain BC04), reducing blood glucose (strain VHProbi C08), lowering blood sugar and uric acid (strain XY01), and anti-aging effects with intestinal flora regulation (strain CCFM1041). Additional patents cover treatment of functional gastrointestinal disorders when combined with Bacillus subtilis spores. Commercial evidence shows use in two cosmetic products from one brand in 2019. These sources indicate a broad evidence base across metabolic, digestive, and skin health applications, though all are patent-based claims.
How is Bacillus coagulans used clinically?
For use as an alkalinizing agent
Which formulation trade-offs should researchers consider for bacillus coagulans?
Key formulation trade-offs center on stabilization and delivery. Patent evidence shows microencapsulation using inulin and xanthan gum, and freeze-drying with protectants such as skim milk powder, fructooligosaccharides, and monosodium glutamate. These methods aim to preserve viability but add complexity and cost. The organism is often combined with prebiotics like fructooligosaccharides, galactooligosaccharides, and inulin, which may require balancing ratios. In supplement compositions, Bacillus coagulans is used at low levels (0.1-1 part by weight per 100 parts prebiotics), indicating that over-formulation may be unnecessary. Spore-based delivery is a common approach for gastrointestinal applications.
What are the physicochemical properties of Bacillus coagulans?
| Property | Value | Category |
|---|---|---|
| Physical Description | Lactic acid appears as a colorless to yellow odorless syrupy liquid. Corrosive to metals and tissue. Used to make cultured dairy products, as a food preservative, and to make chemicals, Dry Powder; Liquid; Liquid; Other Solid, Colourless or yellowish, nearly odourless, syrupy liquid to solid, Thick liquid or crystals, colorless to yellow; mp = 17 deg C, VISCOUS COLOURLESS-TO-YELLOW LIQUID OR COLOURLESS-TO-YELLOW CRYSTALS, colourless to yellow hygroscopic crystals becoming syrupy liquid; odourless | Appearance |
| Color/Form | Crystals (melt at 16.8 °C), Yellow to colorless crystals or syrupy 50% liquid, Viscous, colorless to yellow liquid or colorless to yellow crystals | Appearance |
| Odor | Odorless, Weak unpleasant odor, Available forms have very slightly acrid odor | Appearance |
| Taste | Mild acid taste and does not overpower weaker aromatic flavors, Taste is acrid | Appearance |
| Solubility | 1000000 mg/L, Completely soluble in water, Miscible with water, Completely soluble in ethanol, diethyl ether, and other organic solvents which are miscible with water. It is virtually insoluble in benzene and chloroform, Miscible with glycerol, Soluble in alcohol and furfurol; slightly soluble in ether; insoluble in chloroform, petroleum ether, carbon disulfide. Miscible with alcohol-ether solution, Solubility in water: miscible, miscible with water, glycerol, glycols, oils, miscible at room temperature (in ethanol) | Formulation Relevant Properties |
| LogP | -0.72, log Kow = -0.72, -0.6 | Formulation Relevant Properties |
| pH | The pH of a 10 wt% aqueous solution of lactic acid is 1.75 | Formulation Relevant Properties |
| pKa | 3.86 (at 20 °C) | Formulation Relevant Properties |
| Dissociation Constants | pKa = 3.86 at 20 °C | Formulation Relevant Properties |
| Boiling Point | 122 °C at 1.50E+01 mm Hg, 122 °C at 15 mm Hg, 122 °C (15 mm Hg) | Handling Relevant Properties |
Which formulation benchmark best contextualizes bacillus coagulans, and what differs?
A relevant formulation benchmark is the microencapsulated probiotic powder format. Patent CN117958435B describes a specific method using inulin and xanthan gum as wall materials, with freeze-drying to create microcapsules. This differs from simpler freeze-dried powder formats that use protectants like skim milk powder, fructooligosaccharides, and monosodium glutamate. The microencapsulation approach adds a homogenization and pre-cooling step, potentially offering better protection but requiring more processing. Another benchmark is the spore-based combination with Bacillus subtilis for gastrointestinal disorders, which uses defined spore ratios (1:1, 1:2, or 2:1) rather than microencapsulation.